Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View Item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).

Thumbnail
View/Open
Accepted version (621.1Kb)
Publication Date
2017-06-01
ICR Author
Huddart, Robert
Author
Shamash, J
Sarker, S-J
Huddart, R
Harland, S
Joffe, JK
Mazhar, D
Birtle, A
White, J
Chowdhury, K
Wilson, P
Marshall, MR
Vinnicombe, S
Type
Journal Article
Metadata
Show full item record
Abstract
Background: Bleomycin is an integral part of combination chemotherapy in germ cell tumours. Pulmonary toxicity often necessitates drug cessation and death occurs in 1%-2% of patients. A continuous infusion of bleomycin might reduce lung toxicity when compared with the conventional weekly boluses given as part of standard BEP chemotherapy. Patients and methods: A phase 3 trial was conducted based on 212 men with IGCCCG good prognosis metastatic germ cell tumours with 1 : 1 randomization. They were stratified for age, smoking history and renal function. Patients received either conventional BEP with weekly bleomycin (30 000 units/week i.v. bolus) or as a 90 000 unit infusion on day 1 over 72 h. The primary endpoint was CT assessed lung toxicity, secondary endpoints included progression-free survival (PFS), changes in lung function testing and quality of life. Repeated measures mixed effects model was used to analyse the data. Results: CT assessed lung toxicity for the infusional and conventional arm patients were respectively 80% versus 62% at the end of treatment and 54% versus 51% at 1-year post-treatment. There was no significant difference between the two arms for CT assessed lung toxicity (estimated regression coefficient = 1.4, 95% CI: -0.36, 3.16). Older patients had higher toxicity (coefficient = 4.81, 95% CI: 3.04, 6.58). Lung toxicity increased after 1 cycle and peaked at end of treatment (P ≤ 0.002) and then declined. Lung function testing did not predict for subsequent lung damage. The median follow-up was 2.5 years. Two-year PFS rate (infusional: 93%, conventional: 94%; hazard ratio =0.91, 95% CI: 0.33, 2.52) was similar. Cough (P = 0.002) but not shortness of breath (P ≥ 0.09) was associated with bleomycin toxicity. Conclusions: Infusional bleomycin has no advantage over standard administration. It supports abandoning routine pulmonary function testing, instead the presence of cough should be sought and the early use of CT scanning of the chest to evaluate potential lung toxicity is preferred.
URL
https://repository.icr.ac.uk/handle/internal/614
Collections
  • Radiotherapy and Imaging
Licenseref URL
http://www.rioxx.net/licenses/all-rights-reserved
Version of record
10.1093/annonc/mdx071
Subject
bleomycin
germ cell tumour
infusion
lung
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
Bleomycin
Child
Cisplatin
Etoposide
Humans
Infusions, Intravenous
Lung
Male
Middle Aged
Neoplasm Metastasis
Neoplasms, Germ Cell and Embryonal
Prognosis
Retrospective Studies
Tomography, X-Ray Computed
Young Adult
Research team
Clinical Academic Radiotherapy (Huddart)
Language
eng
Date accepted
2017-02-21
License start date
2017-06-01
Citation
Ann Oncol, 2017, 28 (6), pp. 1333 - 1338

Browse

All of ICR repositoryICR Divisions & RM Clinical UnitsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.